56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 71-72

Background

Neoadjuvant chemotherapy (NAC) and neoadjuvant endocrine therapy (NET) have become mainstays in the treatment of estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer, though most trials have lacked sufficient representation of minority populations. We sought to evaluate predictive factors that correlate with achieving breast and nodal pathologic complete response (pCR) in node-positive, ER+/HER2- breast cancer within a diverse, multiracial patient population.

Methods

We conducted a retrospective chart review on patients with ER+/HER2-, node-positive breast cancer receiving NAC and surgery at a single institution in the Bronx, a highly diverse county (56% Hispanic, 30% Black, 10% White, 4% Other). We did a comprehensive chart review on patients who were diagnosed between July 2016 and May 2022 to assess variables that may correlate with patient outcomes (eg, age, menopausal status, race).

Results

Chemotherapy Type and Patient Disposition Relating to Outcomes

Chemotherapy Type and Patient Disposition Relating to Outcomes

There were 99 patients in this retrospective cohort, with a median age at diagnosis of 59.5 years. There were 22 premenopausal patients, 73 postmenopausal patients, and 4 male patients. Forty-seven (47.5%) patients were Hispanic, 31 (31.3%) Black, 16 (16.2%) White, 2 (2.0%) Asian, and 3 (3.0%) other. Sixty-three patients received NAC, 24 had NET, and 12 had both. Limited testing for proliferative parameters was observed in this population, with oncotype and Ki-67 only available for 9 (9.1%) and 21 (21.2%) of the patients, respectively. Twenty-four (24.2%) patients achieved a nodal pCR and 8 (8.1%) patients achieved a breast pCR. There were no statistically significant differences between nodal pCR rates when patients were stratified by race: 27.6% of Hispanic, 19.4% of Black, 25.0% of White, and 50% of Asian patients achieved a nodal pCR. NAC was superior to NET in achieving nodal pCRs (P = .002) across patient subgroups, including postmenopausal women (P = .006).

Conclusions

In this diverse cohort, nodal pCRs were achieved equally among races, with NAC more effective than NET regardless of menopausal status. Larger studies assessing the predictiveness of proliferative parameters such as Ki-67 and oncotype in minority groups are needed.

Articles in this issue

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast  Cancer in the United States by Palliative Care Utilization
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
64 Empowering Medical Students to Deliver Breast Health Education:  A Community-Based Initiative
64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the  PREDICT Study
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study
67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting
67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table